Page 85 - 83_01

Targeting inflammation in the retina: a new therapeutic approach in diabetic retinopathy

!

Figure 2. IL4/IL13 (M2 cytokines) prevented the pro-inflammatory effects of LPS in Bv-2 microglia cells. Bv-2 cells were treated
with LPS (200 ng/ml) in the absence or presence of IL4/IL13 (20 ng/ml each). A) Nitrites in the culture medium. B) Western blot for
arginase-1 and iNOS. C) mRNA levels of TNFa, IL1ß, IL6 and iNOS. Results are expressed as 2-?Ct. Results are means ± SEM (n=5
independent experiments); *p=0.05 LPS+M2 vs LPS.

Figure 3. Sp2-iminosugar dodecylsulfoxide R-DS-ONJ (compound 5) prevented LPS-mediated effects in Bv-2 microglia cells and

increased arginase-1 in retinal explants. Bv-2 cells were treated with LPS (200 ng/ml) in the absence or presence of (1R)-1-
dodecylsulfinyl-5N,6O-oxomethylidenenojirimycin (R-DS-ONJ, referred as C5 in the figures) at the indicated doses. A) Chemical
structure of C5 compound. B) Crystal violet staining. C) Nitrites accumulation. D) Western blot for iNOS using a-Tubulin as a loading
control. E) mRNA levels of TNFa, IL1ß, IL6 and iNOS. Results are expressed as 2-?Ct. Results are means ± SEM (n=5 independent
experiments); *p=0.05 LPS+R-DS-ONJ vs LPS.

@Real Academia Nacional de Farmacia. Spain 85